Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Annotation

Hayashi-Takagi A, Araki Y, Nakamura M, Vollrath B, Duron SG, Yan Z, Kasai H, Huganir RL, Campbell DA, Sawa A. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci U S A . 2014 Apr 29 ; 111(17):6461-6. PubMed Abstract

Comments on Paper and Primary News
Comment by:  Albert H. C. Wong
Submitted 16 April 2014 Posted 16 April 2014

These are very interesting and novel results using knowledge of DISC1 and dendritic spine biology to test new drugs targeting a pathway implicated in schizophrenia. It is encouraging to see successful, mechanism-based approaches to discover new therapeutic interventions for schizophrenia. Although there is a long road to clinical translation, efforts such as these offer hope that drugs with new targets will emerge. The preventative potential of the PAK inhibitors is also very important, since all current treatments are symptomatic and do not change the course of illness.

View all comments by Albert H. C. Wong


Comment by:  Amy Ramsey
Submitted 23 April 2014 Posted 23 April 2014

New Research Identifies PAK1 as a Promising Target for Schizophrenia Treatment
Schizophrenia has been described as a disease of the synapse, in part because postmortem brain studies have uncovered a loss of dendritic spines, the physical structures of glutamate synapses (Glantz and Lewis, 2000; Sweet et al., 2009; Garey et al., 1998). Interestingly, the same deficits in dendritic spines are seen in a number of pharmacological and genetic animal models of the disorder (Lee et al., 2011; Ramsey et al., 2011; Elsworth et al., 2011; Chen et al., 2008). Despite these intriguing observations, it has been difficult to move beyond correlations to show that spine deficits cause schizophrenia symptoms, and that reversing these deficits will reverse...  Read more


View all comments by Amy Ramsey
Submit a Comment on this Paper
Make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend this paper

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


 
 
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
 
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright